© Alibion AG 2018

Management Team

Daniel Rojas 

CEO

Daniel was introduced to technology commercialization through participation in the “Student Network for Technology Commercialization” program at The University of North Carolina at Chapel Hill. He gained experience in the evaluation of university IP based on market size, competition and product differentiation. As a “Financial analyst” for Moody’s Analytics, he produced marketing materials and valuation models for investments in biotechnology companies. He further complemented these skills with experience in Roche, where he managed relationships and negotiated contracts with international clinical-stage research vendors. Daniel holds a MSc. in Toxicology from the University of North Carolina and an MBA from the University of St. Gallen (HSG).

Liliane Goetsch, PhD

CSO

Liliane is an innovative and results-focused professional with 25 years of industry experience supporting drug discovery, research, and pre-clinical development programs. She brings key project management strengths, decision-making abilities and experience leading multifunctional teams. During her career, she has directed and overseen complex innovative projects from the initial discovery to clinical trials, leveraged with research departments, GMP production, QC management, legal, IP as well as physician teams (internal or academic). She has lead 2 early-stage projects that have been successfully out-licensed to big pharma companies (MSD and AbbVie). Liliane’s strong publication record includes more than 50 peer-reviewed publications and 30 patents. Liliane holds a PhD in Cellular Biology from  Université Claude Bernard Lyon 1, Lyon, France.

Scientific Advisors

Prof. Pierre Miossec

 

Prof. Pierre Miossec is currently Professor of Clinical Immunology at the University of Lyon 1, and head of a clinical unit at the Hospital Edouard Herriot, Lyon, France. Since 2002, he is the director of the Research institute on immuno-genomics and inflammation in Lyon, France, whose goal is to better predict how patients will respond to treatment. His work has always combined care of patients with inflammatory and autoimmune conditions and research on the same topics.

 

He obtained his MD in 1983 from Brest University Hospital before going on to work as a research fellow in the Department of Internal Medicine, Rheumatic Diseases Unit, University of Texas. He received his PhD in Immunology from the University of Marseille in 1987, before going on to work as an associate, and later Professor, of Clinical Immunology at the Claude Bernard University, Lyon. He was the first to identify the destructive properties of Interleukin 17 and to introduce the concept of its production by a new T cell subset.

Through his basic, clinical research and thought leadership, Prof. Miossec has had a great impact on the Rheumatology field. As a prolific researcher, he has authored more than 300 scientific papers. He received the EULAR Robecchi Prize for Rheumatology Research in 1995 and in 2010 the most prestigious Carol Nachman prize in Rheumatology for his contributions to the field. In 2015 he received the distinguished basic investigator award of the American College of Rheumatology and in 2016 the Gerald Weissmann prize from New York University. In 2011, he was elected senior member of the Institut Universitaire de France and in 2016 membre correspondant de l’Académie Nationale de Médecine.

Prof. Joseph Holoshitz

Dr. Holoshitz is a Professor of Internal Medicine and Associate Chief of Rheumatology Research at the University of Michigan. He is responsible for the research leading to the discovery of ALB001 through the study of the mechanistic basis of the association between RA and a certain genetic sequence called the “shared epitope”. He discovered that the rheumatoid arthritis (RA) shared epitope (SE) is capable of altering important signaling events through binding of a cell surface receptor. Dr. Holoshitz dedicates his time to basic and translational research as well as to the attention of patients. 

He pursued his medical education at the Hebrew University-Hadassah Medical School in 1981 and his residency at the Meir Hospital, Internal Medicine in 1984. He completed a fellowship in Rheumatology/Immunology at the Stanford University School of Medicine in 1989. 

Dr. Andy White​

Dr White is a Research Associate Professor of Medicinal Chemistry and Co-director of the Vahlteich Medicinal Chemistry Core at the University of Michigan. He is an experienced medicinal chemistry project leader with a proven track record of multiple quality compounds provided for development on a variety of therapeutic areas. He is an excellent strategic thinker and problem solver in drug discovery, very familiar with the scholarship of key partner lines (Biology, DMPK, Pharmaceutical Sciences, Toxicology, Translational Medicine, Legal). He is experienced in leveraging Contract Research Organizations (CRO’s) in multiple disciplines to deliver quality results. As an expert user of structure-based drug design tools, he holds more than 45 patents (25 issued US patents). Dr. White teaches key Drug Discovery fundamentals in several forums (Designing for efficient use of lipophilicity, Designing for low dose, structural alert mitigation, projecting human dose). Dr. White completed his PhD in Chemistry at the Imperial College London in 1987.